Trastuzumab-Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies.

Cancers (Basel) · 2025 · PMC12610873 · PMID 41228298

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

a favorable trendp = 0.098so close (0.05 < p ≤ 0.1)

A favorable trend was observed in real-world PFS for patients treated with T-DXd as first- or second-line therapy compared with later lines (17 versus 15 months; p = 0.098).

also in 1,335 other papers

did not reach statistical significanceno p-value reported

Another study specifically evaluating MBC patients with both HER2-positive and HER2-low disease reported no significant difference in ORR between the two groups, although a trend toward longer PFS was observed in HER2-positive patients; however, this did not reach statistical significance [ 21 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.